Jack Higgins Sells 9,438 Shares of Immunome (NASDAQ:IMNM) Stock

Immunome, Inc. (NASDAQ:IMNM) insider Jack Higgins sold 9,438 shares of the business’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $21.64, for a total transaction of $204,238.32. Following the completion of the sale, the insider owned 22,000 shares in the company, valued at $476,080. The trade was a 30.02% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Immunome Stock Performance

IMNM stock remained flat at $21.84 on Friday. 1,600,134 shares of the company traded hands, compared to its average volume of 1,582,220. The firm has a market cap of $2.47 billion, a PE ratio of -9.02 and a beta of 2.13. Immunome, Inc. has a fifty-two week low of $5.15 and a fifty-two week high of $27.65. The stock’s fifty day moving average is $22.42 and its two-hundred day moving average is $19.13.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings results on Tuesday, March 3rd. The company reported ($0.75) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.65) by ($0.10). On average, equities analysts expect that Immunome, Inc. will post -2.21 EPS for the current year.

Institutional Investors Weigh In On Immunome

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Assetmark Inc. acquired a new stake in shares of Immunome during the 3rd quarter valued at $39,000. BNP Paribas Financial Markets grew its holdings in shares of Immunome by 81.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 6,464 shares of the company’s stock valued at $60,000 after acquiring an additional 2,909 shares in the last quarter. Strs Ohio acquired a new position in shares of Immunome in the fourth quarter worth $64,000. Tower Research Capital LLC TRC increased its stake in shares of Immunome by 121.2% in the second quarter. Tower Research Capital LLC TRC now owns 6,938 shares of the company’s stock worth $65,000 after acquiring an additional 3,802 shares during the last quarter. Finally, BIT Capital GmbH purchased a new stake in shares of Immunome during the third quarter worth $69,000. Hedge funds and other institutional investors own 44.58% of the company’s stock.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on IMNM shares. Guggenheim boosted their target price on Immunome from $25.00 to $35.00 and gave the stock a “buy” rating in a research report on Tuesday, December 16th. Craig Hallum increased their price target on Immunome from $33.00 to $36.00 and gave the company a “buy” rating in a research report on Wednesday, March 4th. Lake Street Capital lifted their price target on Immunome from $22.00 to $32.00 and gave the stock a “buy” rating in a research note on Tuesday, December 16th. Wedbush restated an “outperform” rating and set a $31.00 price objective on shares of Immunome in a report on Thursday, January 15th. Finally, HC Wainwright started coverage on shares of Immunome in a research note on Thursday, February 12th. They set a “buy” rating and a $40.00 price objective for the company. Ten analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $33.45.

Immunome Company Profile

Immunome, Inc is a clinical-stage biotechnology company focused on discovering and developing novel antibody-based therapeutics for oncology and infectious diseases. The company leverages a proprietary platform that mines the natural B-cell repertoire of patients with active disease to identify fully human monoclonal antibodies with unique mechanisms of action. Immunome’s approach is designed to uncover antibodies that engage the immune system in ways that traditional discovery methods may miss, enabling the development of therapies with potential for improved efficacy and safety profiles.

The company’s lead oncology program, IMM-BCP-01, is a multi-antibody cocktail currently in early-stage clinical trials targeting breast cancer antigens.